The in vitro screening was performed on total memory CD4+ and CD8+ T cells from the matched blood samples from the acute and recovery stages of the disease of 15 patients with AIDP who had distinct potential infection triggers, including SARS-CoV-2 (non-COVID-19 and post-COVID-19 GBS) (Extended Data Tables 1 and 2)). This evidence concerns the gene CD4 and Guillain-Barre syndrome, familial.